Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 18/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.39 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13707351 | 0.78 | ADORA2A (0.43) | ADORA2AADORA3ADORA2BADORA1 | |
| SCHEMBL29980525 | 0.78 | ADORA2A (0.43) | ADORA2AADORA3ADORA2BADORA1 | |
| SCHEMBL4044550 | 0.75 | ADORA2A (0.62) | ADORA2AADORA3ADORA2BADORA1 | |
| SCHEMBL29051638 | 0.72 | ADORA2A (0.60) | ADORA2AADORA1 | |
| SCHEMBL30514650 | 0.72 | ADORA2A (0.60) | ADORA2AADORA1 | |
| SCHEMBL4045282 | 0.71 | ADORA2A (0.46) | ADORA2AADORA3ADORA2BADORA1 | |
| SCHEMBL21814372 | 0.70 | ADORA2A (0.48) | ADORA2AADORA1 | |
| SCHEMBL30738272 | 0.69 | ADORA2A (0.42) | ADORA2AADORA3ADORA2BADORA1 | |
| SCHEMBL20392820 | 0.69 | ADORA2A (0.42) | ADORA2AADORA3ADORA2BADORA1 | |
| SCHEMBL4047491 | 0.69 | ADORA2A (0.33) | ADORA2AADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1392312-B1 | TRIAZOLO 4,5-d PYRIMIDINE DERIVATIVES AND THEIR USE AS PURINERGIC RECEPTOR ANTAGONISTS | VERNALIS RES LTD (GB) | 2009-03-04 | — | — | EP | claimed |
| US-7141575-B2 | Triazolo[4,5-d]pyrimidine derivatives and their use as purinergic receptor antagonists | VERNALIS RESEARCH LTD. (GB) | 2006-11-28 | — | — | US | claimed |
| US-20040097526-A1 | Triazolo[4,5-d]pyrimidine derivatives and their use as purinergic receptor antagonists | VERNALIS DEVELOPMENT LIMITED (GB) | 2004-05-20 | — | — | US | claimed |
| US-20230100842-A1 | TRIAZOLO[4,5-D] PYRAMIDINE DERIVATIVES AND THEIR USE AS PURINE RECEPTOR ANTAGONISTS | LIGAND UK DEVELOPMENT LIMITED (GB) | 2023-03-30 | — | — | US | disclosed |
| US-11466019-B2 | Triazolo[4,5-d] pyramidine derivatives and their use as purine receptor antagonists | VERNALIS (R&D) LIMITED (GB) | 2022-10-11 | — | — | US | disclosed |
| US-20210115054-A1 | TRIAZOLO[4,5-D] PYRAMIDINE DERIVATIVES AND THEIR USE AS PURINE RECEPTOR ANTAGONISTS | VERNALIS (R&D) LIMITED (GB) | 2021-04-22 | — | — | US | disclosed |
| US-20210115054-A1 | TRIAZOLO[4,5-D] PYRAMIDINE DERIVATIVES AND THEIR USE AS PURINE RECEPTOR ANTAGONISTS | VERNALIS (R&D) LIMITED (GB) | 2021-04-22 | — | — | US | disclosed |
| US-10875868-B2 | Triazolo[4,5-d] pyramidine derivatives and their use as purine receptor antagonists | VERNALIS (R&D) LIMITED (GB) | 2020-12-29 | — | — | US | disclosed |
| US-20200172547-A1 | TRIAZOLO[4,5-D] PYRAMIDINE DERIVATIVES AND THEIR USE AS PURINE RECEPTOR ANTAGONISTS | VERNALIS (R&D) LIMITED (GB) | 2020-06-04 | — | — | US | disclosed |
| US-20200172547-A1 | TRIAZOLO[4,5-D] PYRAMIDINE DERIVATIVES AND THEIR USE AS PURINE RECEPTOR ANTAGONISTS | VERNALIS (R&D) LIMITED (GB) | 2020-06-04 | — | — | US | disclosed |
| US-10538526-B2 | Triazolo[4,5-D] pyramidine derivatives and their use as purine receptor antagonists | VERNALIS (R&D) LIMITED (GB) | 2020-01-21 | — | — | US | disclosed |
| US-20110172252-A1 | TRIAZOLO[4,5-D]PYRAMIDINE DERIVATIVES AND THEIR USE AS PURINE RECEPTOR ANTAGONISTS | VERNALIS RESEARCH LIMITED | 2011-07-14 | — | — | US | disclosed |
| EP-2321321-A1 | TRIAZOLO [4, 5-D]PYRAMIDINE DERIVATIVES AND THEIR USE AS PURINE RECEPTOR ANTAGONISTS | Vernalis (R&D) Limited (GB) | 2011-05-18 | — | — | EP | disclosed |
| WO-2009156737-A1 | TRIAZOLO [4, 5-D] PYRAMIDINE DERIVATIVES AND THEIR USE AS PURINE RECEPTOR ANTAGONISTS | VERNALIS (R&D) LIMITED (GB) | 2009-12-30 | — | — | WO | disclosed |
| US-7589097-B2 | Triazol[4,5-d] pyramidine derivatives and their use as purinergic receptor antagonists | VERNALIS RESEARCH LIMITED (GB) | 2009-09-15 | — | — | US | disclosed |
| EP-1392312-B1 | TRIAZOLO 4,5-d PYRIMIDINE DERIVATIVES AND THEIR USE AS PURINERGIC RECEPTOR ANTAGONISTS | VERNALIS RES LTD (GB) | 2009-03-04 | — | — | EP | disclosed |
| US-20080234296-A1 | Triazolo[4,5-d] pyramidine derivatives and their use as purinergic receptor antagonists | VERNALIS RESEARCH LIMITED | 2008-09-25 | — | — | US | disclosed |
| US-7405219-B2 | Triazolo [4,5-d] pyrimidine derivatives and their use as purinergic receptor antagonists | VERNALIS RESEARCH LIMITED (GB) | 2008-07-29 | — | — | US | disclosed |
| US-20070049607-A1 | Triazolo [4,5-d] pyrimidine derivatives and their use as purinergic receptor antagonists | VERNALIS RESEARCH LIMITED | 2007-03-01 | — | — | US | disclosed |
| US-7141575-B2 | Triazolo[4,5-d]pyrimidine derivatives and their use as purinergic receptor antagonists | VERNALIS RESEARCH LTD. (GB) | 2006-11-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234296-A1 | Triazolo[4,5-d] pyramidine derivatives and their use as purinergic receptor antagonists | CHRNA5, ADORA2A, CHRNA4 | ADORA2A 2/4885ADORA3 4/4885ADORA2B 12/4885 |
| US-20110172252-A1 | TRIAZOLO[4,5-D]PYRAMIDINE DERIVATIVES AND THEIR USE AS PURINE RECEPTOR ANTAGONISTS | P2RX5, P2RY1, P2RX3 | ADORA2A 11/4885ADORA3 14/4885ADORA2B 19/4885 |
| US-20070049607-A1 | Triazolo [4,5-d] pyrimidine derivatives and their use as purinergic receptor antagonists | CHRNA5, ADORA2A, CHRNA4 | ADORA2A 2/4885ADORA3 6/4885ADORA2B 11/4885 |
| US-10875868-B2 | Triazolo[4,5-d] pyramidine derivatives and their use as purine receptor antagonists | P2RX5, P2RY1, P2RX3 | ADORA2A 11/4885ADORA3 14/4885ADORA2B 19/4885 |
| US-20210115054-A1 | TRIAZOLO[4,5-D] PYRAMIDINE DERIVATIVES AND THEIR USE AS PURINE RECEPTOR ANTAGONISTS | P2RX5, P2RY1, P2RX3 | ADORA2A 11/4885ADORA3 14/4885ADORA2B 19/4885 |
| US-20040097526-A1 | Triazolo[4,5-d]pyrimidine derivatives and their use as purinergic receptor antagonists | CHRNA5, CHRNA4, CNR1 | ADORA2A 7/4885ADORA3 17/4885ADORA2B 40/4885 |
| US-10538526-B2 | Triazolo[4,5-D] pyramidine derivatives and their use as purine receptor antagonists | P2RX5, P2RY1, P2RX3 | ADORA2A 11/4885ADORA3 14/4885ADORA2B 19/4885 |
| US-11466019-B2 | Triazolo[4,5-d] pyramidine derivatives and their use as purine receptor antagonists | P2RX5, P2RY1, P2RX3 | ADORA2A 11/4885ADORA3 14/4885ADORA2B 19/4885 |
| US-20230100842-A1 | TRIAZOLO[4,5-D] PYRAMIDINE DERIVATIVES AND THEIR USE AS PURINE RECEPTOR ANTAGONISTS | P2RX5, P2RY1, P2RX3 | ADORA2A 11/4885ADORA3 14/4885ADORA2B 19/4885 |
| US-20200172547-A1 | TRIAZOLO[4,5-D] PYRAMIDINE DERIVATIVES AND THEIR USE AS PURINE RECEPTOR ANTAGONISTS | P2RX5, P2RY1, P2RX3 | ADORA2A 11/4885ADORA3 14/4885ADORA2B 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.